MJA
MJA InSight
MJA Careers
Public health

Mass psychogenic response to human papillomavirus vaccination

Jim P Buttery, Simon Madin, Nigel W Crawford, Sonja Elia, Sophie La Vincente, Sarah Hanieh, Lindsay Smith and Bruce Bolam
Med J Aust 2008; 189 (5): 261-262.

Cervical cancer associated with human papillomavirus (HPV) affects approximately 1000 Australian women each year, causing about 300 deaths.1 The newly licensed HPV vaccines Gardasil (CSL Limited), a quadrivalent vaccine (4vHPV), and Cervarix (GlaxoSmithKline Vaccines), a bivalent vaccine (2vHPV), induce protection against the two most common strains of HPV, which cause 70% of all cervi

Jim P Buttery, MB BS, MSc, FRACP, Infectious Diseases Physician1,2,3
Simon Madin, MB BS, Immunisation Manager4
Nigel W Crawford, MB BS, FRACP, MPH, Paediatrician1,2,3
Sonja Elia, RN, Nursing Coordinator1,3,5
Sophie La Vincente, MSc, MAE Student1,5
Sarah Hanieh, MB BS, Infectious Diseases Fellow2,3
Lindsay Smith, MB BS, FRACP, Neurologist6
Bruce Bolam, MB BS, MPH, Public Health Trainee4
1 SAEFVIC, Murdoch Childrens Research Institute, Royal Children’s Hospital, Melbourne, VIC.
2 Department of Paediatrics, University of Melbourne, Melbourne, VIC.
3 Infectious Diseases Unit and Immunisation Service, Department of General Medicine, Royal Children’s Hospital, Melbourne, VIC.
4 Victorian Department of Human Services, Melbourne, VIC.
5 National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT.
6 Department of Paediatric Neurology, Monash Medical Centre, Melbourne, VIC.
Article References: 
Reference Text: 
Australian Institute of Health and Welfare. Cancer in Australia 2001. Canberra: AIHW, 2004. (AIHW Cat. No. CAN 23; Cancer series No. 28.)
Reference Order: 
1
PubMed ID: 
Reference Text: 
Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-1255.
Reference Order: 
2
PubMed ID: 
16631880
Reference Text: 
Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
Reference Order: 
3
PubMed ID: 
17494925
Reference Text: 
Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369: 1693-1702.
Reference Order: 
4
PubMed ID: 
17512854
Reference Text: 
Clements CJ. Mass psychogenic illness after vaccination. Drug Saf 2003; 26: 599-604.
Reference Order: 
5
PubMed ID: 
12814329
Reference Text: 
Tanne JH. Questions over human papillomavirus vaccine in the US and Australia. BMJ 2007; 334: 1182-1183.
Reference Order: 
6
PubMed ID: 
17556447
Reference Text: 
Clements CJ. Gardasil and mass psychogenic illness. Aust N Z J Public Health 2007; 31: 387.
Reference Order: 
7
PubMed ID: 
17725025

The full contents of this page are only available to subscribers.